西点药业(301130)8月14日披露2025年半年度报告，报告期内，公司实现营业收入1.28亿元，同比减少 0.51%;实现归属于上市公司股东的净利润2494.46万元，同比增长2.02%;实现归属于上市公司股东的扣除 非经常性损益的净利润2338.6万元，同比增长12.26%;基本每股收益0.33元。 西点药业表示，业绩变动主要原因是公司积极开拓市场，重点产品瑞香素胶囊、利培酮口崩片销售收入 增长，同时持续提升经营管理水平，降低总体费用率，提高盈利水平。 西点药业主要从事化学原料药及制剂的研发、生产和销售，公司专注于在老年高发慢性病精准治疗药 品、补铁制剂、治疗循环障碍药品、抗精神疾病用药领域及原料药的研发与制造，「原料药+制剂」一 体化优势突出，致力于成为国内银发健康用药市场及补血用药市场、精神障碍用药市场具有竞争力的化 学药品生产企业。 截至2025年6月30日，公司拥有29个制剂品种(36个规格)的药品注册批件以及16个原料药注册批件，重 点涵盖老年高发慢性病精准治疗药品、抗贫血用药、治疗循环障碍用药、治疗精神障碍用药以及原料药 生产领域。 值得一提的是，瑞香素胶囊是西点药业的核心产品之一，属于治疗 ...

Core Viewpoint - The announcement indicates that Harbin Zhenbao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhenbao Island (603567), has received approval from the National Medical Products Administration for the transfer of marketing authorization for ten drugs from Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to Harbin Zhenbao Pharmaceutical Co., Ltd. This change is not expected to have a significant impact on the company's current operating performance [1]. Group 1 - The approval includes the transfer of marketing authorization for ten drugs, which are Olanzapine Tablets, Apixaban Tablets, Escitalopram Oxalate Tablets, Desloratadine Tablets, Voriconazole Tablets, Mecobalamin Tablets, Rivaroxaban Tablets, Valsartan Tablets, and Donepezil Hydrochloride Tablets [1]. - The change in marketing authorization holders is a strategic move for Harbin Zhenbao Pharmaceutical Co., Ltd. to consolidate its product portfolio [1]. - The company emphasizes that this regulatory approval will not materially affect its current financial performance [1].